Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Homology Medicines, Inc. operates as a genetic medicines company. The Company offers a platform to utilize human hematopoietic stem cell derived adeno-associated virus vectors to treat a range of disease-causing mutations through gene correction, insertion, and knockout. Homology Medicines serves patients in the United States.
Website: homologymedicines.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 42.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -4 166.7%. Gross margin is low, -59.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.36 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -14.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2 311.0% higher than minimum and 9.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -199.9x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FIXX
Share price, USD:  (-0.2%)12.8
year average price 2.12  


year start price 0.93 2025-09-26

min close price 0.93 2025-09-26

max close price 14.15 2026-08-19

current price 12.80 2026-09-25
Common stocks: 58 017 411

Dividend Yield:  0.0%
EV / Sales: 231.5x
Margin (EBITDA LTM / Revenue): -4 166.7%
Fundamental value created in LTM:
Market Cap ($m): 743
Net Debt ($m): -48
EV (Enterprise Value): 695
Price to Book: -40.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-05-11Zacks Investment Research

Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-06 2024-05-09 2023-11-14 2023-08-14 2023-05-11 2022-11-10
acceptedDate 2025-11-13 07:09:18 2025-08-06 07:08:40 2025-03-11 07:18:16 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47 2022-03-23 16:01:27 2021-03-11 16:04:47
calendarYear 2025 2025 2024 2023 2023 2023 2022
period Q3 Q2 FY Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 0 0 1M 0 354 000 802 000 3M 802 000 34M 3M
costOfRevenue 0 0 0 0 578 000 136 000 564 000 0 3M 0 10M 100M
grossProfit 0 0 0 0 578 000 -136 000 -210 000 802 000 609 000 802 000 24M -98M
grossProfitRatio 0 0 0 0 -0.593 1 1
researchAndDevelopmentExpenses 4M 5M 48M 10M 62M 18M 23M 20M 98M 26M 93M 100M
generalAndAdministrativeExpenses 4M 4M 18M 5M 31M 7M 8M 8M 38M 8M 37M 33M
sellingAndMarketingExpenses 0 0 0 0 -578 000 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 4M 4M 18M 5M 31M 7M 8M 8M 38M 8M 37M 33M
otherExpenses 0 0 0 0 0 7M 0 0 0 0 0 0
operatingExpenses 8M 9M 66M 15M 93M 31M 31M 28M 136M 34M 130M 133M
costAndExpenses 0 0 0 15M 93M 31M 31M 28M 136M 34M 130M 133M
interestIncome 0 0 0 0 6M 1M 2M 1M 3M 1M 185 000 2M
interestExpense 0 0 0 0 0 0 0 -1M 0 1M 0 0
depreciationAndAmortization 118 000 0 0 29 000 578 000 136 000 217 000 225 000 -130M 321 000 8M 8M
ebitda -7M -9M -66M -15M -92M -31M -31M -27M -133M -33M -88M -122M
ebitdaratio 0 0 0 0 -86.438 -34.022 -40.575
operatingIncome -8M -9M -66M -15M -92M -31M -31M -28M -133M -33M -96M -130M
operatingIncomeRatio 0 0 0 0 -87.051 -34.303 -40.975
totalOtherIncomeExpensesNet 188 000 -318 000 20M 16M 14M 1M 2M 1M 134M 1M 185 000 2M
incomeBeforeTax -7M -9M -46M 1M -87M -30M -29M -26M 1M -32M -96M -129M
incomeBeforeTaxRatio 0 0 0 0 -82.782 -32.471 -39.393
incomeTaxExpense 0 0 -21 000 176 000 26M 3M 6M 3M 715 000 -46 000 -185 000 -2M
netIncome -7M -9M -48M 1M -113M -33M -35M -29M 483 000 -32M -96M -127M
netIncomeRatio 0 0 0 0 -98.994 -35.965 -39.335
eps -0.6 -0.78 -5.12 1.03 -351.57 -0.57 -0.61 -0.5 1.51 -0.55 -311.2 -498.41
epsdiluted -0.6 -0.78 0.44 -0.57 -0.61 -0.5 -0.55
weightedAverageShsOut 12M 12M 9M 995 280 321 304 58M 58M 58M 318 887 57M 307 129 255 059
weightedAverageShsOutDil 12M 12M 10M 2M 321 304 58M 58M 58M 318 887 57M 307 129 255 059
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-13 2023-03-09 2022-03-23 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 0 6M 3M 185 000 2M
ebit 0 -92M -259M -96M -130M
nonOperatingIncomeExcludingInterest 0 0 126M 0 0
netIncomeFromContinuingOperations 0 -113M 483 000 -96M -127M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 -5M -185 000 0
netIncomeDeductions 0 0 -5M -185 000 0
bottomLineNetIncome -48M -113M 483 000 -96M -127M
epsDiluted -4.94 -351.57 1.51 -311.2 -498.41

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-06 2024-05-09 2023-11-14 2023-08-14 2023-05-11 2022-11-10
acceptedDate 2025-11-13 07:09:18 2025-08-06 07:08:40 2025-03-11 07:18:16 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47 2022-03-23 16:01:27 2021-03-11 16:04:47
calendarYear 2025 2025 2024 2023 2023 2023 2022
period Q3 Q2 FY Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 49M 55M 78M 116M 39M 29M 77M 39M 34M 43M 108M 217M
shortTermInvestments 0 0 0 20M 43M 74M 50M 111M 141M 158M 47M 0
cashAndShortTermInvestments 49M 55M 78M 135M 83M 103M 127M 150M 175M 201M 156M 217M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 400 000
inventory 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 2M 3M 4M 3M 1M 3M 4M 4M 6M 12M 36M 2M
totalCurrentAssets 51M 58M 82M 138M 84M 107M 131M 154M 181M 213M 192M 220M
propertyPlantEquipmentNet 6M 7M 7M 8M 650 000 19M 21M 21M 22M 22M 18M 43M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 14M 17M 23M 26M 27M 2M 1M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 647 000 1M 3M 6M 0 0 -38M 0 -47M 0 0 0
totalNonCurrentAssets 7M 8M 10M 14M 222M 33M 38M 44M 47M 49M 20M 44M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 58M 66M 92M 152M 306M 140M 169M 198M 228M 263M 212M 264M
accountPayables 973 000 910 000 3M 5M 3M 8M 3M 4M 1M 5M 2M 5M
shortTermDebt 6M 6M 3M 3M 1M 2M 2M 2M 2M 1M 246 000 3M
taxPayables 0 0 0 0 0 0 0 0 0 816 000 0 0
deferredRevenue 0 0 0 0 0 0 0 354 000 1M 2M 3M 6M
otherCurrentLiabilities 4M 4M 10M 25M 7M 16M 18M 13M 19M 17M 11M 10M
totalCurrentLiabilities 11M 12M 16M 33M 12M 25M 23M 19M 23M 25M 17M 23M
longTermDebt 5M 5M 6M 6M 0 27M 27M 27M 28M 28M 24M 13M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 1M 32M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 222M 0 0 0 0 0 0 0
otherNonCurrentLiabilities 60M 62M 65M 65M 0 0 0 0 0 20M 0 0
totalNonCurrentLiabilities 65M 67M 70M 71M 222M 27M 27M 27M 28M 28M 25M 45M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 28M 29M 29M 0 30M 0 0
totalLiabilities 76M 78M 87M 104M 233M 52M 50M 46M 50M 54M 42M 68M
preferredStock 0 0 92M 152M 0 0 0 0 0 0 0 0
commonStock 2000 2000 2000 2000 6000 6000 6000 6000 6000 6000 6000 5000
retainedEarnings -263M -255M -235M -186M -542M -526M -493M -458M -429M -395M -424M -328M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 -5000 -5000 -36 000 -88 000 -182 000 -404 000 -457 000 -7000 0
othertotalStockholdersEquity 244M 243M 82M 614M 612M 610M 604M
totalStockholdersEquity -18M -12M 6M 49M 73M 88M 119M 152M 178M 209M 170M 196M
totalEquity -18M -12M 6M 49M 73M 88M 119M 152M 178M 209M 170M 196M
totalLiabilitiesAndStockholdersEquity 58M 66M 152M 140M 169M 198M 263M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 58M 66M 92M 152M 306M 140M 169M 198M 228M 263M 212M 264M
totalInvestments 0 0 0 20M 43M 74M 50M 111M 167M 185M 49M 1M
totalDebt 11M 12M 9M 9M 1M 28M 29M 29M 29M 30M 24M 15M
netDebt -38M -43M -69M -106M -38M -773 000 -48M -10M -5M -13M -84M -202M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-13 2023-03-09 2022-03-23 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 400 000
prepaids 0 0 0 0 -400 000
totalPayables 3M 3M 1M 2M 5M
otherPayables 0 0 0 0 0
accruedExpenses 0 0 0 0 0
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 240M 615M 608M 594M 524M

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX FIXX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-13 2025-08-06 2024-05-09 2023-11-14 2023-08-14 2023-05-11 2022-11-10
acceptedDate 2025-11-13 07:09:18 2025-08-06 07:08:40 2025-03-11 07:18:16 2024-05-09 07:18:33 2024-03-12 21:56:33 2023-11-14 16:00:32 2023-08-14 16:01:01 2023-05-11 16:00:57 2023-03-09 16:01:13 2022-11-10 16:01:47 2022-03-23 16:01:27 2021-03-11 16:04:47
calendarYear 2025 2025 2024 2023 2023 2023 2022
period Q3 Q2 FY Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -11M -6M -48M 1M -113M -33M -35M -29M -5M -34M -96M -129M
depreciationAndAmortization 118 000 -23 000 -27 000 29 000 578 000 136 000 217 000 225 000 1M 321 000 8M 8M
deferredIncomeTax 0 0 0 0 0 3M 5M 0 0 0 1M 690 000
stockBasedCompensation 1M 1M 4M 417 000 7M 2M 2M 2M 13M 3M 17M 13M
changeInWorkingCapital 974 000 -974 000 0 0 -7M 3M 3M -2M 3M 4M -42M 12M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 2M -4M -1M 928 000 2M 4M -242 000 2M -981 000 1M -2M 2M
otherWorkingCapital -757 000 757 000 0 0 -9M -1M 4M -5M 4M 3M -39M 9M
otherNonCashItems 5M -6M -24M 0 18M 365 000 364 000 2M -126M 2M 1M 939 000
netCashProvidedByOperatingActivities -3M -12M -68M -15M -96M -25M -24M -26M -114M -25M -110M -94M
investmentsInPropertyPlantAndEquipment -2000 2000 -75 000 0 -228 000 -338 000 0 -228 000 -1M -6000 -2M -4M
acquisitionsNet 0 0 0 0 0 338 000 0 0 130M 0 48M -209M
purchasesOfInvestments 0 0 0 0 -73M -48M 1000 -25M -157M -108M -97M -20M
salesMaturitiesOfInvestments 0 0 20M 97 000 174M 25M 61M 57M 65M 0 49M 229M
otherInvestingActivites 0 0 0 338 000 0 0 0
netCashUsedForInvestingActivites -2000 2000 97 000 -23M 61M 31M -108M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 0 0 42M 18 000 2000 0 0
commonStockRepurchased 0 0 0 0 0 0 0 150 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -1M -317 000 99M 0 0 0 124 000
netCashUsedProvidedByFinancingActivities -1M -317 000 99M 18 000 2000 150 000 124 000
effectOfForexChangesOnCash 0 0 0 0 0 15M 0 0 0 0 0 0
netChangeInCash -6M -23M 47M 85M 5M -48M 37M 5M -76M -133M -108M 164M
cashAtEndOfPeriod 50M 55M 79M 116M 39M 29M 77M 39M 34M 43M 110M 219M
cashAtBeginningOfPeriod 55M 79M 31M 31M 34M 77M 39M 34M 110M 176M 219M 55M
operatingCashFlow -3M -12M -68M -15M -96M -25M -24M -26M -114M -25M -110M -94M
capitalExpenditure -2000 2000 -75 000 0 -228 000 -338 000 0 -228 000 -1M -6000 -2M -4M
freeCashFlow -3M -12M -68M -15M -96M -25M -24M -26M -115M -25M -112M -98M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link
filingDate 2025-03-11 2024-03-13 2023-03-09 2022-03-23 2021-03-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 38M -48M 209M
netCashProvidedByInvestingActivities 20M 101M 37M -51M 205M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 0 0 0 0 0
netCommonStockIssuance 0 0 0 0 0
commonStockIssuance 42M 184 000 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 95M 184 000 596 000 52M 53M
netCashProvidedByFinancingActivities 95M 184 000 596 000 52M 53M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

Press-releases

Show financial reports only

2024-03-18 20:30 ET
Homology Medicines Declares Distribution to Common Stockholders
2024-01-03 21:08 ET
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
2023-11-16 12:05 ET
Q32 Bio and Homology Medicines Announce Merger Agreement
2023-11-16 12:05 ET
Q32 Bio and Homology Medicines Announce Merger Agreement
2023-11-14 21:33 ET
Homology Medicines Reports Third Quarter 2023 Financial Results
2023-08-14 20:05 ET
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights
2023-07-27 20:05 ET
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU
2023-07-27 20:01 ET
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU
2023-05-16 12:00 ET
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting
2023-05-11 20:05 ET
Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights
2023-05-03 11:30 ET
Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting
2023-03-15 20:01 ET
Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting
2023-03-09 21:05 ET
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
2023-03-09 13:00 ET
Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer
2023-03-02 12:30 ET
Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference
2023-02-22 21:01 ET
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium™ Meeting
2023-01-04 21:01 ET
Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
2022-11-10 21:07 ET
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
2022-10-27 13:00 ET
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
2022-10-06 12:30 ET
Homology Medicines to Participate at Upcoming Conferences
2022-09-06 20:01 ET
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
2022-08-15 20:10 ET
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
2022-08-11 20:05 ET
Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
2022-07-05 12:30 ET
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
2022-06-29 12:00 ET
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
2022-06-13 12:00 ET
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
2022-05-18 10:00 ET
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
2022-05-16 20:15 ET
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
2022-05-02 20:56 ET
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
2022-04-21 12:30 ET
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
2022-03-23 20:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
2022-03-10 21:01 ET
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica
2022-03-03 12:30 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2022-02-18 21:05 ET
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU
2022-02-10 16:40 ET
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting
2022-01-28 07:30 ET
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner
2021-11-15 12:10 ET
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights
2021-11-03 12:28 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2021-10-21 11:00 ET
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting
2021-10-20 12:30 ET
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting
2021-10-18 12:30 ET
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome)
2021-10-12 20:05 ET
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU
2021-08-12 20:05 ET
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights
2021-08-05 12:30 ET
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board
2021-08-04 12:30 ET
Homology Medicines to Participate in Upcoming Investor Conferences
2021-05-13 11:00 ET
Homology Medicines Announces Presentations on its Expanding Genetic Medicines Platform and Internal GMP Manufacturing at the American Society of Gene & Cell Therapy Annual Meeting
2021-05-06 20:05 ET
Homology Medicines Reports First Quarter 2021 Financial Results and Recent Highlights
2021-05-03 12:00 ET
Homology Medicines Presents Data Demonstrating In Vivo Transduction of Non-Human Primate and Human Retinal Cells at ARVO Annual Meeting
2021-04-28 12:00 ET
Homology Medicines Announces New Approach to Leverage AAVHSC Platform by Delivering One-Time In Vivo Gene Therapy to Produce Antibodies in Humanized Murine Model
2021-04-14 12:30 ET
Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting
2021-04-12 12:30 ET
Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
2021-04-07 12:52 ET
Homology Medicines Announces Pricing of Public Offering of Common Stock
2021-04-06 20:19 ET
Homology Medicines Announces Proposed Public Offering of Common Stock
2021-03-11 21:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
2021-03-01 12:30 ET
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
2021-02-25 13:00 ET
Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences
2021-02-08 19:50 ET
Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome
2021-01-06 13:00 ET
Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
2020-11-09 21:05 ET
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
2020-11-09 13:00 ET
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
2020-11-06 16:40 ET
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
2020-11-05 14:15 ET
Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU
2020-10-22 12:30 ET
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
2020-09-18 13:00 ET
Homology Medicines to Participate in Upcoming Conferences
2020-08-10 20:05 ET
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
2020-07-21 12:00 ET
Homology Medicines Appoints Jeff Poulton to the Board of Directors
2020-05-26 18:10 ET
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program
2020-05-12 12:00 ET
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting
2020-05-07 20:05 ET
Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
2020-04-29 12:00 ET
Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting
2020-03-16 13:00 ET
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model
2020-03-12 20:10 ET
Homology Medicines Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
2020-02-20 14:00 ET
Homology Medicines to Participate in Upcoming Investor and Scientific Conferences
2020-02-13 14:00 ET
Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders
2019-12-17 21:01 ET
Homology Medicines Announces Encouraging Initial Clinical Data from its pheNIX Gene Therapy Trial for PKU
2019-12-16 14:00 ET
Homology Medicines Announces Peer-Reviewed Publication of Five-Year Retrospective Study Conducted in Collaboration with Two PKU Key Opinion Leaders Demonstrating Substantially Elevated Phe Levels in Adults with Classical PKU on Standard of Care
2019-12-03 13:30 ET
Homology Medicines Announces Appointment of Gabriel M. Cohn, M.D., as Chief Medical Officer
2019-11-26 20:00 ET
Homology Medicines Announces Peer-Reviewed Publication Demonstrating its AAVHSC Vectors Crossed the Blood-Brain-Barrier and Blood-Nerve-Barrier in NHPs
2019-11-12 21:09 ET
Homology Medicines Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-25 12:30 ET
Homology Medicines Presents Preclinical Data From Its Investigational PKU Gene Editing Program, Demonstrating Phenotypic Correction and Molecular Confirmation of Editing Precision
2019-10-21 12:30 ET
Homology Medicines Presents Data from Investigational PKU and MLD Gene Therapy Programs that Demonstrate Preclinical Proof-of-Concept for Potential One-Time Therapies
2019-09-30 12:49 ET
Homology Medicines to Participate in Conferences in October
2019-04-04 20:05 ET
Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production
2019-04-04 11:00 ET
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
2019-03-19 12:39 ET
Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day
2019-03-12 11:13 ET
Homology Medicines Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Recent Accomplishments
2019-03-06 13:30 ET
Homology Medicines to Present at Cowen Healthcare Conference
2019-01-07 14:25 ET
Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019

SEC forms

Show financial reports only

SEC form 10
2026-08-05 11:09 ET
Homology Medicines reported for 2026 q2
SEC form 8
2026-08-05 11:02 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-08-05 11:02 ET
Homology Medicines reported for 2026 q2
SEC form 8
2026-07-15 21:18 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-15 21:18 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-15 21:18 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-15 21:18 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-13 12:39 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-13 12:39 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-13 11:09 ET
Homology Medicines published news for 2026 q2
SEC form 8
2026-07-13 11:09 ET
Homology Medicines published news for 2026 q2
SEC form 10
2026-05-05 11:14 ET
Homology Medicines reported for 2026 q1
SEC form 8
2026-05-05 11:04 ET
Homology Medicines published news for 2026 q1
SEC form 8
2026-05-05 11:04 ET
Homology Medicines reported for 2026 q1
SEC form 8
2026-04-24 20:09 ET
Homology Medicines published news for 2026 q1
SEC form 8
2026-04-24 20:09 ET
Homology Medicines published news for 2026 q1
SEC form 8
2026-03-27 21:15 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-03-27 21:15 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-03-27 21:15 ET
Homology Medicines published news for 2025 q4
SEC form 10
2026-03-10 11:14 ET
Homology Medicines reported for 2025 q4
SEC form 8
2026-03-10 11:05 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-03-10 11:05 ET
Homology Medicines reported for 2025 q4
SEC form 8
2026-02-17 21:18 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-02-17 21:18 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-02-17 21:18 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-02-17 21:18 ET
Homology Medicines published news for 2025 q4
SEC form 8
2026-02-17 21:18 ET
Homology Medicines published news for 2025 q4
SEC form 10
2025-11-13 07:09 ET
Homology Medicines reported for 2025 q3
SEC form 8
2025-11-13 07:03 ET
Homology Medicines published news for 2025 q3
SEC form 8
2025-11-13 07:03 ET
Homology Medicines reported for 2025 q3
SEC form 8
2025-10-21 11:05 ET
Homology Medicines published news for 2025 q3
SEC form 8
2025-10-21 11:05 ET
Homology Medicines published news for 2025 q3
SEC form 10
2025-08-06 11:08 ET
Homology Medicines reported for 2025 q2
SEC form 8
2025-08-06 11:03 ET
Homology Medicines published news for 2025 q2
SEC form 8
2025-08-06 11:03 ET
Homology Medicines reported for 2025 q2
SEC form 10
2025-05-08 11:11 ET
Homology Medicines reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Homology Medicines reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Homology Medicines published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Homology Medicines reported for 2025 q1
SEC form 10
2025-03-11 11:18 ET
Homology Medicines reported for 2024 q4
SEC form 10
2025-03-11 00:00 ET
Homology Medicines reported for 2024 q4
SEC form 8
2025-03-11 00:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-03-11 00:00 ET
Homology Medicines reported for 2024 q4
SEC form 8
2025-03-10 11:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-03-10 11:00 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-02-10 21:14 ET
Homology Medicines published news for 2024 q4
SEC form 8
2025-02-10 21:14 ET
Homology Medicines published news for 2024 q4
SEC form 10
2024-11-07 07:16 ET
Homology Medicines reported for 2024 q3
SEC form 8
2024-11-07 07:05 ET
Homology Medicines published news for 2024 q3
SEC form 8
2024-11-07 07:05 ET
Homology Medicines reported for 2024 q3
SEC form 10
2024-08-08 00:00 ET
Homology Medicines reported for 2024 q2
SEC form 8
2024-08-08 00:00 ET
Homology Medicines published news for 2024 q2
SEC form 8
2024-08-08 00:00 ET
Homology Medicines published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Homology Medicines reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Homology Medicines published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Homology Medicines published news for 2024 q1
SEC form 10
2024-03-13 00:00 ET
Homology Medicines reported for 2023 q4
SEC form 10
2024-03-12 21:56 ET
Homology Medicines reported for 2023 q4
SEC form 10
2023-11-14 16:00 ET
Homology Medicines reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Homology Medicines reported for 2023 q3
SEC form 10
2023-08-14 16:01 ET
Homology Medicines reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Homology Medicines reported for 2023 q2
SEC form 6
2023-07-27 17:29 ET
Homology Medicines published news for 2023 q2
SEC form 6
2023-06-15 19:25 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:33 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:17 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-15 18:04 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-06-14 16:06 ET
Homology Medicines published news for 2023 q1
SEC form 10
2023-05-11 16:00 ET
Homology Medicines reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Homology Medicines reported for 2023 q1
SEC form 6
2023-04-28 16:00 ET
Homology Medicines published news for 2023 q1
SEC form 6
2023-03-16 17:03 ET
Homology Medicines published news for 2022 q4
SEC form 10
2023-03-09 16:01 ET
Homology Medicines reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Homology Medicines reported for 2022 q4
SEC form 6
2023-01-04 17:07 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:37 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:36 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:34 ET
Homology Medicines published news for 2022 q4
SEC form 6
2023-01-04 16:32 ET
Homology Medicines published news for 2022 q4
SEC form 10
2022-11-10 16:01 ET
Homology Medicines reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Homology Medicines reported for 2022 q3
SEC form 6
2022-09-08 16:05 ET
Homology Medicines published news for 2022 q2
SEC form 6
2022-09-08 16:03 ET
Homology Medicines published news for 2022 q2
SEC form 10
2022-08-15 16:04 ET
Homology Medicines reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Homology Medicines reported for 2022 q2
SEC form 6
2022-06-16 16:05 ET
Homology Medicines published news for 2022 q1
SEC form 6
2022-06-13 08:20 ET
Homology Medicines published news for 2022 q1
SEC form 10
2022-05-16 16:03 ET
Homology Medicines reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Homology Medicines reported for 2022 q1
SEC form 6
2022-04-29 16:04 ET
Homology Medicines published news for 2022 q1
SEC form 6
2022-04-21 17:20 ET
Homology Medicines published news for 2022 q1
SEC form 10
2022-03-23 16:01 ET
Homology Medicines published news for 2021 q4
SEC form 10
2022-03-23 00:00 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-16 16:06 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-03-11 16:05 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-02-18 16:16 ET
Homology Medicines published news for 2021 q4
SEC form 6
2022-02-02 17:36 ET
Homology Medicines published news for 2021 q4
SEC form 10
2021-11-15 07:01 ET
Homology Medicines published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Homology Medicines published news for 2021 q3
SEC form 10
2021-08-12 16:02 ET
Homology Medicines published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Homology Medicines published news for 2021 q2
SEC form 6
2021-06-21 17:02 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-05-06 16:02 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-29 16:01 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-12 16:05 ET
Homology Medicines published news for 2021 q1
SEC form 6
2021-04-09 16:45 ET
Homology Medicines published news for 2021 q1
SEC form 10
2021-03-11 16:04 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-03-01 17:02 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-02-08 16:07 ET
Homology Medicines published news for 2020 q4
SEC form 6
2021-01-06 08:01 ET
Homology Medicines published news for 2020 q4
SEC form 6
2020-12-18 16:01 ET
Homology Medicines published news for 2020 q3
SEC form 10
2020-11-09 16:02 ET
Homology Medicines published news for 2020 q3
SEC form 6
2020-11-09 08:26 ET
Homology Medicines published news for 2020 q3